Unit-dose, alcohol-free formulation designed to support precise dosing and ease of administration across pediatric, geriatric, dysphagic, and institutional care settings [Fort Lauderdale, FL] — [March Day, 2026] — Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the U.S. launch of Sdamlo™ (amlodipine for oral solution), […]

Clinically proven to treat Generalized Anxiety Disorder (GAD), Bucapsol™ (buspirone HCl) delivers effective, sustained symptom relief without sedation, cognitive dulling, or risk of dependency—empowering patients to stay functional, focused, and in control. FORT LAUDERDALE, FL — July 17, 2025 — Pangea Pharmaceuticals is pleased to announce the nationwide launch of Bucapsol™ (buspirone HCl) Oral Capsules, […]

Pangea Pharmaceuticals Expands Access to Ergomar® Sublingual Tablets, Reinforcing Commitment to Patients and Providers. FORT LAUDERDALE, FL — June 10, 2025 — Pangea Pharmaceuticals is pleased to share continued momentum and expanded access for Ergomar® Sublingual Tablets (2 mg; Ergotamine Tartrate, USP; ANDA 087693), a unique migraine and cluster headache therapy that has gained significant traction since […]

Bridging Tradition and Forward-Thinking Solutions to Shape the Future of Healthcare Pangea Pharmaceuticals, a dynamic and forward-thinking pharmaceutical company, is reshaping the healthcare landscape with its innovative approach to drug development, distribution, and patient access. Founded in 2018 by industry veterans Anthony LaViola (CEO) and Steve Flood (President), Pangea Pharmaceuticals combines cutting-edge pharmaceutical solutions with […]